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Abstract Treatment options for patients with high-risk acute
myeloid leukemia (AML) include high-dose chemotherapy
regimens in combination with allogeneic hematopoietic stem
cell transplantation, which takes advantage of the donor T-
cell-mediated graft-versus-leukemia effect. Together with
beneficial responses observed in assays targeted at
leukemia-associated antigens (LAA), this encouraged
research on cancer vaccines and adoptive cellular therapies
in AML. The receptor for hyaluronic acid-mediated motility
(RHAMM, CD168) was identified as one of the most
promising LAA in AML. Thus far, little is known about in
situ expression in leukemic bone marrow blasts or the
prognostic role of RHAMM and its interaction partners in
AML. We immunohistochemically analyzed the expression
and prognostic significance of RHAMM on trephine bone
marrow biopsies from 71 AML cases that had been evaluated
for cytogenetics and presence of FLT3-internal tandem
duplications and NPM1 mutations. Fifty-five patients
(77%) were treated with curative intent, while 16 (23%)
received the most appropriate supportive care. Twenty of 71
(28%) AML cases were considered RHAMM+. Receiver
operating characteristic curves showed significant discrimi-
natory power considering overall survival (OS) in AML
patients treated curatively for RHAMM (p=0.015). Multi-
variable analysis revealed that expression of RHAMM in
>5% of leukemic blasts identifies a subgroup of curatively
treated cases with adverse OS independent of failures to
achieve complete remission. RHAMM not only represents a
promising LAAwith specific T-cell responses in AML but, if
assessed in situ on blasts, also a probable prognostic factor.
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Introduction
Acute myeloid leukemias (AML) are neoplastic hemato-
poietic stem cell disorders characterized by maturation
arrest, uncontrolled proliferation, and resistance to apopto-
sis [1, 2]. Decision making for treatment of AML patients is
risk adapted to the World Health Organization (WHO)
defined “clinico-pathologic-genetic” entities [3, 4] and
further depends on the patient’s health status and age.
Treatment options range from best supportive care to
intensive multiagent chemotherapy alone or high-dose
regimens in combination with, primarily, allogeneic hema-
topoietic stem cell transplantation (allo-HSCT) [5]. In the
latter, the graft-versus-leukemia effect suggests that leukemia-
specific T lymphocytes play a major role in attacking and
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eliminating leukemic cells, thus supporting long-term
remission. Along with several observed immunological
and clinical responses using assays targeted at leukemia-
associated antigens, these observations encouraged research
on cancer vaccines and adoptive cellular therapies in AML
[6–8]. The receptor for hyaluronic acid-mediated motility
(RHAMM, CD168) was identified as one of the most
promising leukemia-associated antigens in AML [7, 9–13].
RHAMM has several known functions that vary with respect
to its different interaction partners. Interaction with CD44 in
the presence of hyaluronic acid plays a role in cellular
motility, wound healing, and modification of the Rat
sarcoma (Ras)-signaling cascade [14–17]. Through interac-
tions with signaling cascades related to extracellular signal-
regulated protein kinase 1/2 (ERK1/2), breast cancer 1
(BRCA1), and BRCA1-associated RING domain 1
(BARD1), RHAMM, alone or in complex with CD44,
osteopontin (OPN), and integrins, can promote cancer cell
invasion and is essential for tumorigenicity, most likely by
oncogenic inhibition of apoptosis [13–15, 18–23]. Further-
more, intracellular RHAMM is expressed in a cell cycle-
dependent manner and helps maintaining genomic stability,
thus acting as a tumor suppressor [21, 24]. Finally, as a
surface molecule on tumor cells, RHAMM has been shown
to play an important role in humoral anti-tumor responses
[11, 25]. RHAMM has been identified as an important
prognostic factor of significance in carcinomas and lympho-
mas, and also in leukemias [10, 25–33]. A study of Greiner
et al. suggested a probable but statistically not significant
favorable prognostic impact of elevated RHAMM mRNA
expression in AML [7].
Along with RHAMM, CD44, a transmembrane glyco-
protein, is also a receptor for hyaluronic acid. CD44 can
interact with various molecules, like OPN, matrix metal-
loproteinases, CD95, and also with extracellular RHAMM
to promote invasion, angiogenesis, inflammation, and
apoptotic resistance [19, 33, 34]. Like RHAMM, CD44 is
involved in signaling pathways including cellular sarcoma
(c-Src) family kinases and Ras-like family GTPases [34].
CD44 arouse attention in AML research when a monoclo-
nal antibody against this molecule eradicated AML stem
cells [35].
Despite the potentially promising observations on
RHAMM in AML, little is known about its in situ expression
on bone marrow blasts or its prognostic significance. In
addition, there are no data on the expression of its interaction
partners, OPN, CD44 and signal transducers, and activators
of transcription (STAT), or about its influence on the rate of
spontaneous apoptosis in AML. Therefore, we performed
immunohistochemical analyses on bone marrow trephine
biopsies from a cohort of 71 AML cases to determine the
expression and prognostic importance of RHAMM and
interacting molecules.
Patients, materials, and methods
Patients
A retrospective cohort of 71 patients with AML was
analyzed. All newly diagnosed patients with AML between
2005 and 2007 at the University Hospital Basel, who had
been fully evaluated for cytogenetics and molecular
markers, including the presence of internal tandem dupli-
cations of FMS-like tyrosine kinase 3 (FLT3-ITD) and, in
cases with normal cytogenetics, for Nucleophosmin 1
(NPM1) mutations, were included in this study if paraffin
blocks of the bone marrow trephine biopsies were ade-
quately preserved for immunohistochemical analyses. All
cases were reclassified according to WHO criteria [4].
Clinical and follow-up data were obtained by reviewing the
charts. Retrieval of tissue and clinical data were performed
according to data safety laws.
Of the 71 patients included in this study, 33 were male
(mean age 58, median age 57, range 26–95) and 38
female (mean age 56, median 59, range 20–89). Therapy
was risk adapted to the “clinico-pathologic-genetic” AML
entity and to the patient’s health status according to the
protocols of the Dutch-Belgian Cooperative Trial Group
for Hematology and Oncology (HOVON, http://www.
hovon.nl/trials/trials-by-type/aml.html) at the time of diag-
nosis. The distribution of cases according to the WHO
classification is presented in Table 1. Responses to
treatment were defined as published by the International
Working Group for Diagnosis, Standardization of Response
Criteria, Treatment Outcomes, and Reporting Standards for
Therapeutic Trials in AML [36].
Cytogenetic analysis was performed at the Centre
Hospitalier Universitaire Vaudois in Lausanne (Unité
cytogénétique du cancer). Karyotypes were described
according to the International System for Human Cytoge-
netic Nomenclature [37]. Cases were grouped according to
cytogenetics into three risk groups as suggested by
Grimwade [38]. FLT3-ITD and NMP1 mutation analysis
was performed as described [39].
Immunohistochemical staining
Paraffin blocks of the 71 bone marrow trephine biopsies
were processed in a standardized manner for immunohis-
tochemistry. Eight cases with reactive bone marrow
changes (non-hemolytic anemia and thrombocytopenia)
served as controls. Table 2 lists the primary antibodies
used as well as the incubation and pre-treatment conditions.
Visualization of bound secondary antibodies was done by
avidin–biotin–peroxidase techniques using either diamino-
benzidine (DAB) or aminoethylcarbazole (AEC) as chrom-
ogens. Since the staining intensity varied between cases
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[40, 41], only the relative proportion (percentage) of
positively staining tumor cells was quantified. To study
reproducibility of stainings, a second observer reassessed
20% of cases.
Statistics
Statistical analyses were performed using SPSS version 15.0
(SPSS, Chicago, IL). Incomplete data were not excluded from
the tests. The degree of agreement between the observers for
the quantitative immunohistochemical values was evaluated
by intra/interclass correlation coefficients using the
Cronbach’s alpha analysis. The Spearman’s test was used to
analyze relationships between the markers. Only correlation
coefficients >0.300 or <−0.300 were further considered. The
Fisher’s exact test was used to analyze differences in
distribution of case numbers between groups. Mann–Whitney
or Kruskal–Wallis tests were applied as appropriate to assess
differences of means between groups. The prognostic
performance of the variables and determination of optimal
cut-off values was established by receiver operating charac-
teristic (ROC curves plotting sensitivity versus 1-specificity
with special consideration of the respective area under the
ROC (AUROC)). The optimal cut-off point was calculated
using Youden’s index (Y), denoting Y = sensitivity +
specificity − 1, since this method can be applied to find the
optimal cut-off value with the highest sensitivity and
specificity when there is no particular requirement on
sensitivity and/or specificity [42]. OS was analyzed by the
Kaplan–Meier method and compared by the log-rank test in
univariable modus and by the Cox’ regression analysis in
multivariable modus. Only factors that were determined to
be of at least trend prognostic significance in the univariable
modus (p<0.1) were entered into the multivariable analysis.
Statistical significance was defined as p<0.05 and corrected
for multiple testing, when necessary. Two-sided tests were
used throughout.
Results
Response to therapy and clinical outcomes
The average follow-up time was 16.7 months (median 10;
range 0−62). Within this time, 32 patients died. Most of the
patients (n=55) were treated with curative intent (chemo-
therapy alone: n=25; intensive chemotherapy followed by
autologous HSCT: n=4; intensive chemotherapy followed
by allo-HSCT: n=26). Sixteen patients did not qualify for
intensive treatment. Five were given hydroxyurea and the
others received best supportive care. The mean OS of
patients treated without intention to cure was 4.4 months
and the median 1.3 months, while the OS of patients treatedT
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with intention to cure was 45.3 months (mean) and the
median was not reached. Of the 55 patients treated with
curative intent, 29 achieved a complete remission after
induction, 12 a partial remission, while 14 had a resistant
disease. Responses to induction therapy did not correlate
with leukemia subtype, neither subtypes according to WHO
nor with Grimwade’s prognostic groups [4, 38], patients’
age, regimen composition nor any of the studied phenotypic
and genetic markers. Failure to achieve complete remission
was a prognostic factor for OS (p=0.039), while patients’
age, gender, leukemia subtype were not, yet the Kaplan–
Meier survival curves indicated poorer outcomes for elderly
patients and patients with therapy-related AML as well as
such with complex karyotypes. These observations were
particularly due to the fact that patients treated with curative
intent were treated in different ways according to their
“clinico-pathologic-genetic” risk and patients being at risk
were treated in a more intensive way, which probably
evened outcomes (Table 1).
One third of AML express cytoplasmic/membranous
RHAMM in approximately 20% of blasts
Assessment of RHAMM and active caspase-3 expression
was highly reproducible (average interobserver correlation
coefficient α=0.92 and 0.89, respectively), and that of
panCD44 and OPN was good (α=0.82 and 0.79, respec-
tively). Except for 10 AML cases that were not assessable
for active caspase-3 quantification, all cases were evaluable
by immunohistochemical analysis.
In reactive bone marrows, panCD44 was expressed in
erythropoietic precursors, as expected [43], and the same was
found with OPN. RHAMM was detectable in single myelo-/
monopoietic precursors and mature mononuclear cells, as
formerly shown [29, 44]. Active caspase-3 stained two to 16
apoptotic bodies per 0.283 mm2, especially in areas rich in
erythropoiesis. Qualitative impression of the various anti-
body staining patterns can be extracted from Fig. 1a and b.
Compared to controls, AML cases showed primarily
qualitative staining differences, expressing the respective
molecules in different cell populations. PanCD44 was
strongly expressed in a mean of 38% of AML blasts in the
16 positive cases (cut-off score >5%), RHAMM in a mean of
19% of AML blasts in the 20 positive cases (cut-off score
>5%) and OPN in 52% of AML blasts in the 35 positive cases
(cut-off score >25%). The sub-cellular localization of stain-
able RHAMM was predominantly cytoplasmic. In AML
cases with blasts negative for the respective marker, there
were few erythropoietic or mononuclear cells remaining,
occasionally expressing panCD44, OPN, or/and RHAMM,
which served as internal positive control. Active caspase-3
stained 0 to 29 apoptotic bodies per 0.283 mm2, which were
morphologically attributable to leukemic blasts. Quantitative
immunohistochemical data are shown in Table 1. Qualitative
impression of the various antibodies’ staining patterns can be
extracted from Fig. 1c–f.
Expression of RHAMM in AML correlates with panCD44,
pSTAT3, and pSTAT5, and with the spontaneous apoptotic
activity
Expression of the analyzed markers was correlated with
each other and to known clinical and pathological param-
eters previously determined on the study collective, such as
WHO leukemia subtype, patient age and gender, lack of
complete remission, expression of pSTAT1, pSTAT3, and
pSTAT5, and presence of FLT3-ITD and NPM1 mutations
[39]. RHAMM correlated with expression of panCD44
(ρ=0.560), of pSTAT3 and pSTAT5 (ρ=0.521 and 0.347,
respectively) and with spontaneous apoptosis as determined
by the expression of active caspase-3 (ρ=0.321). The
correlations of RHAMM and panCD44 as well as pSTAT3
and pSTAT5 expression were also observable in AML with
recurrent genetic aberrations and AML, not otherwise
specified; in addition in AML with normal karyotype and
noncomplex abnormalities according to Grimwade [38],
presence of FLT3-ITD correlated with failures to achieve
complete remiss ion (ρ = 0.504) . In AML with
myelodysplasia-related changes RHAMM correlated with
pSTAT1 expression in blasts (ρ=0.565), while this correla-
tion was weaker (ρ=0.288) in the AML collective as a
whole. There were no correlations between the studied
markers and NPM1 mutation status.
RHAMM is a WHO subtype-, age-, treatment type-,
and response to treatment-independent negative prognostic
factor in AML
Patients treated with curative intent (n=55) and those
receiving best supportive care (n=16) were analyzed
Antibody Clone Source Dilution Retrieval Dye
Active caspase3 AF835 R&D 1:2,000 MW, EDTA pH 8, 100°C, 15′ AEC
OPN OP3N Novocastra 1:50 MW, citrate pH 6, 100°C, 30′ AEC
panCD44 IM7.8.1 ATCC 1:100 MW, citrate pH 6, 100°C, 30′ AEC
RHAMM 2D6 Novocastra 1:25 Bond max, EDTA pH 8, 100°C, 20′ DAB
Table 2 Applied antibodies and
staining conditions
AEC aminoethylcarbazole, DAB
diaminobenzidine, EDTA
ethylenediaminetetraacetate,
MW microwave oven
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separately to exclude treatment effect bias. Of the markers
analyzed, ROC curve-based analysis showed significant
discriminatory power for survival of curatively treated AML
patients only for RHAMM (AUROC = 0.721, p=0.015;
Fig. 2a). In a further step, this was linked to survival by the
Kaplan–Meier method and compared by the log-rank test
using the cut-off score suggested by ROC, i.e., >5% blasts;
the expression of RHAMM showed a significant negative
prognostic effect (Fig. 2b) that was particularly evident in
patients who failed to achieve complete remission after
induction treatment (Fig. 3a and b). Importantly, expression
of RHAMM in patients who did or did not achieve complete
remission was similar, and the lack of complete remission did
not correlate to any of the above-mentioned clinical or
pathological parameters. Analyzed with respect to the
WHO entities and the Grimwade’s cytogenetic prognostic
groups [38], the negative prognostic effect of RHAMM was
apparent in the Kaplan–Meier curves in AML with recurrent
genetic aberrations, in AML, not otherwise specified, in the
favorable risk group AML and in AML with normal
karyotypes and other noncomplex abnormalities (intermediate
risk group) according to Grimwade. Except for AML with
normal karyotypes and other noncomplex abnormalities
(intermediate risk group), where statistical significance was
reached (p=0.029) patient numbers were too low in any of
the groups to draw statistical conclusions. Considering the
type of curative treatment regimens, this effect remained
significant only for patients treated with multiagent chemo-
therapy (p=0.031), and not with high-dose regimens with
HSCT (p=0.119). In a multivariable model, expression of
RHAMM turned out to be a negative prognostic factor
independent of failure to achieve complete remission in
curatively treated AML (p=0.002, relative risk 5.38, 95%
confidence interval 1.75–16.49 for RHAMM; p=0.017,
relative risk 4.23, 95% confidence interval 1.29–13.78 for
failure to achieve complete remission).
Fig. 1 Expression of the
studied markers. a Expression of
panCD44 on erythroid
precursors in normal bone
marrow. b Expression of
RHAMM in a single
mononuclear cell in the normal
bone marrow. c PanCD44-
positive AML. d AML case
with 20% RHAMM-positive
blasts. e Osteopontin-positive
AML. f AML case with
increased (>1%) spontaneous
apoptotic activity as assessed by
the expression of active
caspase-3; all original
magnifications ×400
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Discussion
Our study is the first histopathology-based qualitative and
quantitative examination of the expression of RHAMM and
its partners in AML patients by immunohistochemistry on
trephine bone marrow biopsies. Expression of RHAMM
in >5% of leukemic blasts identified a subgroup of AML
patients (treated curatively) with poor prognoses indepen-
dent of AML WHO subtype or age. This effect was
particularly pronounced in patients who failed to achieve
complete remission after induction therapy. Thus, our
results considerably extend previous data on RHAMM in
AML, showing that RHAMM not only represents a
promising leukemia-associated antigen, similar to the
preferentially expressed antigen in melanoma and the
carbonic anhydrase IX (G250), with specific T-cell
responses that suggest the possibility of tumor vaccination
[11, 13], but also a prognostic tumor-related factor with a
Fig. 2 Prognostic significance of RHAMM in AML. a ROC curve
of the prognostic performance of RHAMM in AML cases treated
with curative intent. The area under the ROC of 0.721 (95%
confidence interval 0.568–0.873) indicates that consideration of
RHAMM is 22% more accurate in predicting survival than a random
guess (p=0.015). The curve point (arrow) at sensitivity of 0.57
(57%) and specificity of 0.775 (77.5%; 1-specificity=0.225) is at
greatest distance from the reference line. The relevant cut-off score
of RHAMM at that point is >5% positive blasts. b Kaplan–Meier
overall survival curves in AML patients treated with curative intent
with respect to the expression of RHAMM; six out of the 37
RHAMM-negative AML patients died, mean survival 52 months,
median not reached, compared to eight out of 17 RHAMM-positive
patients, mean survival 21 months, median 15 months, p=0.006
Fig. 3 Prognostic significance of RHAMM in AML with respect to
treatment responses. Kaplan–Meier overall survival curves in AML
patients achieving (a) and failing to achieve complete remission
(b) with respect to the expression of RHAMM; p=0.391 for (a);
among the patients who failed to achieve complete remission four out
of 20 RHAMM-negative patients died, mean survival 47 months,
median not reached, compared to all six RHAMM-positive patients,
mean survival 10 months, median 9 months, p=0.001 for (b)
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particular prognostic significance for patients failing to
achieve complete remission after induction treatment. The
latter might be of special interest since there are no
established prognostic factors for AML in patients who
failed to achieve complete remission.
RHAMM expression has been shown to be of prognostic
importance in hematological neoplasia like B-cell chronic
lymphocytic leukemia, plasma cell myeloma, and diffuse
large B-cell lymphoma [10, 27–29]. The biological back-
ground of the observed prognostic effects of RHAMM is
not known. Because it is, on the one hand, a surface
receptor molecule, and on the other, a functional intracel-
lular protein, RHAMM plays different roles that vary with
respect to its numerous interaction partners. Together with
CD44, RHAMM promotes cellular motility, wound healing,
and the Ras-signaling cascade [15–17]. Through interac-
tions with signaling related to ERK1/2, BRCA1 and
BARD1, RHAMM, alone or in complexes with CD44,
OPN, and integrins, RHAMM can be tumorigenic, most
likely by inhibition of apoptosis [13–15, 18–23]. In
addition, intracellular RHAMM helps maintaining genomic
stability [21, 24]. Finally, as a surface molecule on tumor
cells, RHAMM has been shown to play an important role in
humoral anti-tumor responses [11, 25].
A former study of Greiner et al. suggest a possible yet
not statistically significant (p=0.284) favorable prognostic
impact of RHAMM in AML [7]. These authors studied
gene expression levels of tumor-associated antigens from
peripheral blood and bone marrow samples utilizing mRNA
quantification of extracts from frozen mononuclear cells.
The probable positive prognostic effect of RHAMM was
attributed to anti-leukemic activity of the immune system
represented by killing residual tumor cells expressing such
tumor-associated antigens. The discrepancy in the observed
prognostic impact of RHAMM between our study and that
of Greiner et al. might be due to the different methodolo-
gies employed to determine RHAMM expression, i.e.,
mRNA quantification and in situ analysis of blast counts
with surface/cytoplasmic protein expression. This could
reflect different RHAMM functions as an oncogene
(surface, cytoplasmic protein), a tumor-suppressor gene
(nuclear protein) or leukemia-associated antigen (surface
and extracellular protein). Lastly, considering the contro-
versies on the prognostic impact of expression levels of
another leukemia-associated antigen, WT1, in the study of
Greiner et al. and previous studies [7, 45, 46], and the
minor, if any, statistical significance of the gene expression
of all studied leukemia-associated antigens in the former
study, the in situ approach chosen in our study might more
ostensibly mirror the oncogenic function of RHAMM in
AML. In our AML collective, RHAMM was predominantly
cytoplasmically expressed in a proportion of blasts, and
closely correlated with expression of CD44 and pSTAT3
and pSTAT5 as well as with spontaneous leukemia
apoptosis, but did not correlate with OPN. This indicates
that RHAMM is probably not constitutively expressed by
all blasts, and that its observed effects might be related to
the interference of OPN-independent RHAMM with AML
cell signaling or locomotion, and rather not with its anti-
apoptotic functions.
In summary, beyond being a promising leukemia-
associated antigen in AML, consideration of RHAMM
surface/cytoplasmic expression in blasts may allow identi-
fication of a subgroup of curatively treated patients with
poor prognosis independent of AML WHO subtype,
especially in patients who failed to achieve complete
remission after induction therapy, which might merit further
evaluation.
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